Multiple Myeloma Therapeutics in Asia-Pacific Market worth 2.8 Billion by 2020

1
Multiple Myeloma Therapeutics in Asia-Pacific
Markets to 2021 - Growth Driven by Rising
Prevalence, Continued Success of Velcade,
Revlimid and Emerging Supplementary Treatments
Published on 01 October, 2015 Number of
pages 117 Single User Price 4995
Over the 20142020 forecast period, the MM
market in Australia, China, India and Japan is
expected to increase in value at a CAGR of 7.4,
from 1.7 billion to about 2.8 billion.
2
Summary of the ReportMultiple Myeloma (MM) is
a hematological malignancy characterized by the
proliferation of plasma cells in the bone marrow.
The disease is incurable although over the past
decade there have been significant improvements
in therapy, driven by a greater understanding of
pathophysiology. MM represents about 0.81 of
all cancer cases worldwide and approximately 10
of all hematological cancers, with incidence
rates ranging from 0.4 to 5 per 100,000 persons
in different parts of the world. Without any
treatment, the median survival of a myeloma
patient is about six months, but this can be
extended with the use of various forms of
treatment. There are now five classes of drugs
used in the treatment of myeloma
immunomodulatory drugs, chemotherapy, proteasome
drugs, Histone Deacetylase (HDAC) inhibitors and
steroids. Many of the notable drugs in these
classes were approved over the past 1015 years.
Treatment using these novel drugs and high-dose
chemotherapy with hematopoietic Stem-Cell
Transplant (SCT) has been shown to improve median
survival to five years, which makes this the
current standard therapy. However, many patients
suffer relapse or develop treatment resistance,
leaving a need to develop safe and effective
treatments that prolong the duration of remission
and improve survival.
Click Here To Check Complete Report
3

• Scope of the Report
• The different segments of patients with MM are
  based on their eligibility for an SCT
• What combination therapies are used for various
  segments?
• What are the treatment options available for
  myeloma, providing an overview of the front-line,
  second-line and third-line therapies available?
• What are the dominant mechanisms of action across
  marketed products?
• Which products are approved currently in each
  country and which ones are likely to be launched
  within the forecast period?
• Which product is used more in each country?
• Will there be any label expansions of existing
  market leaders in any of the countries?
• Epidemiology of MM is significantly different in
  Asia-Pacific countries from that in the major
  markets.
• What are the various epidemiology trends in each
  country?
• What factors contribute to the overall
  epidemiology?
• Which class is most prominent within the
  pipeline?
• Do the pipeline molecules offer an advantage over
  commercially proven mechanisms?
• What are the late-pipeline products expected to
  be launched in each country in the near future?

Download Sample Brochure
4

• Reasons to buy
• This report will enable you to -
• Understand the clinical context of MM by
  considering symptoms, etiology, pathophysiology,
  epidemiology, diagnosis, and treatment options.
• Identify the therapeutic strategies, products,
  and companies that dominate the current marketed
  products landscape and recognize gaps and areas
  of unmet need.
• Consider market opportunities and potential risks
  by examining trends in clinical trial size,
  duration, and failure rate by stage of
  development, molecule type, and mechanism of
  action.
• Recognize the late-stage pipeline molecules that
  have demonstrated strong therapeutic potential by
  examining clinical trial data and multi-scenario
  product forecast projections.
• Compare treatment usage patterns, annual therapy
  costs, and market growth projections for India,
  China, Australia and Japan.
• Discover trends in licensing and co-development
  deals concerning MM products and identify the
  major strategic consolidations that have shaped
  the commercial landscape.

Make an Inquiry Before Buying
5
Multiple Myeloma Therapeutics in Asia-Pacific
Markets to 2021 - Growth Driven by Rising
Prevalence, Continued Success of Velcade,
Revlimid and Emerging Supplementary Treatments
A detailed qualitative analysis of the factors
responsible for driving and restraining growth of
the Multiple Myeloma Therapeutics Market are
provided in the report.
Contact 1-302-684-6088 sales_at_marketintelreports.c
om www.marketintelreports.com
Click here to order a copy of Multiple Myeloma
Therapeutics Market Report